Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC016
- Development stage
- Unknown
- Lead developer
- Haichang Biotech
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
HC016 is an intratumoral lipid complex injection containing a STING (Stimulator of Interferon Genes) agonist, developed by Zhejiang Haichang Biotech. The drug utilizes a specialized lipid delivery system to enhance the stability and uptake of the STING agonist within the tumor microenvironment. Upon administration, HC016 activates the STING pathway, leading to the induction of Type I interferons and pro-inflammatory cytokines. This process facilitates the maturation of antigen-presenting cells and the priming of tumor-specific T-cells, aiming to convert 'cold' tumors into 'hot' tumors and potentially elicit a systemic anti-tumor immune response. It is currently in Phase 1 clinical development for the treatment of advanced or recurrent solid tumors.
- Other names
- HC016 Lipid Complex InjectionHC-016 Lipid Complex InjectionHC 016 Lipid Complex Injection
02
Targets
STING (Stimulator of interferon genes protein)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on HC016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HC016.